MLN 2222

Drug Profile

MLN 2222

Alternative Names: CAB-2; CMI-CAB-2; MLN2222; MLN2222 CAB-2

Latest Information Update: 08 Apr 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer XOMA
  • Class Anti-inflammatories; Recombinant proteins
  • Mechanism of Action Complement system protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Adult respiratory distress syndrome; Inflammation; Reperfusion injury

Most Recent Events

  • 14 May 2008 Takeda acquires Millennium Pharmaceuticals
  • 20 Mar 2006 XOMA has completed a phase I trial in the US
  • 05 Aug 2005 This compound is still in active development - (BIO-2005)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top